Antiphospholipid syndrome in pregnancy

Current Opinion in Obstetrics and Gynecology

Volumn 16, Issue 2, 2004, Pages 129-135

  Carp, Howard J A ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

2 glycoprotein 1 antibodies; Antiphospholipid antibodies; Antiphospholipid syndrome; Aspirin; Heparin; Intravenous immunoglobulin; Low molecular weight heparins; Recurrent miscarriage; Recurrent pregnancy loss

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; HEPARIN; IMMUNOGLOBULIN; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PREDNISONE; STEROID;

ACNE; ANTIPHOSPHOLIPID SYNDROME; CLINICAL TRIAL; CUSHING SYNDROME; FETUS DEATH; GROWTH RETARDATION; HUMAN; INTRAUTERINE GROWTH RETARDATION; OSTEOPOROSIS; PREECLAMPSIA; PREGNANCY; PREMATURE LABOR; PREMATURITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SPONTANEOUS ABORTION; THROMBOCYTOPENIA;

ABORTION, HABITUAL; ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; FEMALE; FETAL DEATH; FETAL GROWTH RETARDATION; GLYCOPROTEINS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 1942454698     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200404000-00006     Document Type: Review

References (74)

1. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification for definite antiphospholipid syndrome. Arthritis Rheum 1999; 42:1309-1311.
2. Ruiz-Irastorza G, Khamashta MA, Hughes GRV. Treatment of pregnancy loss in Hughes syndrome: a critical update. Autoimmun Rev 2002; 1:298-304.
3. Lockshin MD. Antiphospholipid antibody syndrome. JAMA 1992; 268:1451-1453.
4. Stone S, Khamashta MA, Poston L. Placentation, antiphospholipid syndrome and pregnancy outcome. Lupus 2001; 10:67-74.
5. Sanmarco M, Soler C, Christides C, et al. Prevalence and clinical significance of IgG isotype anti-beta 2-glycoprotein I antibodies in anti-phospholipid syndrome: a comparative study with anticardiolipin antibodies. J Lab Clin Med 1997; 129:499-506.
6. Rand JH. The antiphospholipid syndrome. Annu Rev Med 2003; 54:409-424. A review paper which explains the mechanisms of action of aPLs.
7. Galli M, Comfurius P, Barbui T, et al. Anticoagulant activity of β2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost 1992; 68:297-300.
8. Viard JP, Amoura Z, Bach J-F. Association of anti-β2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med 1992; 93:181-186.
9. Carreras LO, Forastiero RR, Martinuzzo ME. Which are the best biological markers of the antiphospholipid syndrome? J Autoimmun 2000; 15:163-172.
10. Pengo V, Biasiolo A, Rampazzo P, Brocco T. dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-beta2- glycoprotein I autoantibodies. Thromb Haemost 1999; 81:256-258.
11. Harris EN, Gharavi AE, Boey ML. Anti-cardiolipin antibodies: detection by radioimmunassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 2:1211-1214.
12. Harris EN, Pierangeli SS. Revisiting the anticardiolipin test and its standardization. Lupus 2002; 11:269-275.
13. Tincani A, Allegri F, Sanmarco M, et al. Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations. A cooperative project of the European Antiphospholipid Forum. Thromb Haemost 2001; 86:575-583.
14. Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci U S A 1991; 88:3069-3073.
15. Bakimer R, Fishman P, Blank M, et al. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J Clin Invest 1992; 89:1558-1563.
16. Ornoy A, Yacobi S, Avraham S, et al. The effect of sera from women with SLE and/or anti phospholipid syndrome on rat embryos in culture. Reprod Toxicol 1998; 12:185-191.
17. Ornoy A, Yacobi S, Tartakover Matalon S, et al. The effects of antiphospholipid antibodies obtained from women with SLE APS and associated pregnancy loss on rat embryos and placental explants in culture. Lupus 2003; 12:573-578. First paper to show that aPL has embryotoxic effects in addition to thrombotic effects.
18. Sheng Y, Reddel SW, Herzog H, et al. Impaired thrombin generation in beta 2-glycoprotein I null mice. J Biol Chem 2001; 276:13817-13821.
19. Shoenfeld Y, Sherer Y, Fishman P. Interleukin-3 and pregnancy loss in antiphospholipid syndrome. Scand J Rheumatol Suppl 1998; 107:19-22.
20. Fishman P, Falach-Vaknine E, Zigelman R, et al. Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interleukin-3. J Clin Invest 1993; 91:1834-1837.
21. Krause I, Blank M, Levi Y, et al. Anti-idiotype immunomodulation of experimental anti-phospholipid syndrome via effect on Th1/Th2 expression. Clin Exp Immunol 1999; 117:190-197.
22. Bertolaccini ML, Atsumi T, Lanchbury JS, et al. Plasma tumor necrosis factor alpha levels and the 238A promoter polymorphism in patients with antiphospholipid syndrome. Thromb Haemost 2001; 85:198-203.
23. Simantov R, LaSala JM, Lo SK, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995; 96:2211-2219.
24. Meroni PL, Raschi E, Camera M, et al. Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome. J Autoimmun 2000; 15:237-240.
25. Pierangeli SS, Espinola RG, Liu X, et al. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and Pselectin. Circ Res 2001; 88:245-250.
26. Voges D, Berendes R, Burger A, et al. Three-dimensional structure of membrane-bound annexin V: a correlative electron microscopy-X-ray crystallography study. J Mol Biol 1994; 238:199-213.
27. Rand JH, Wu XX, Andree HAM, et al. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a 'lupus procoagulant' phenomenon. Blood 1998; 92:1652-1660.
28. Nakamura N, Ban T, Yamaji K, et al. Localization of the apoptosis-inducing activity of lupus anticoagulant in an annexin V-binding antibody subset. J Clin Invest 1998; 101:1951-1959.
29. Combes V, Simon AC, Grau GE, et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 1999; 104:93-102.
30. de-Groot PG, Horbach DA, Derksen RH. Protein C and other cofactors involved in the binding of antiphospholipid antibodies: relation to the pathogenesis of thrombosis. Lupus 1996; 5:488-493.
31. Carreras LO, Vermylen JG. 'Lupus' anticoagulant and thrombosis: possible role of inhibition of prostacyclin formation. Thromb Haemost 1982; 48:38-40.
32. Robbins DL, Leung S, Miller-Blair DJ, et al. Effect of anticardiolipin/beta2-glycoprotein I complexes on production of thromboxane A2 by platelets from patients with the antiphospholipid syndrome. J Rheumatol 1998; 25:51-56.
33. Shoenfeld Y, Blank M. Effect of long-acting thromboxane receptor antagonist (BMS 180,291) on experimental antiphospholipid syndrome. Lupus 1994; 3:397-400.
34. Out HJ, Kooijman CD, Bruinse HW, et al. Histo-pathological findings from patients with intrauterine fetal death and antiphospholipid antibodies. Eur J Obstet Gynecol 1991; 41:179-186.
35. Blank M, Krause I, Fridkin M, et al. Bacterial induction of autoantibodies to beta2-glycoprotein-1 accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 2002; 109:797-804. The first paper to show that APS may have an infectious cause.
36. Manco Johnson MJ, Nuss R, Key N, et al. Lupus anticoagulant and protein S deficiency in children with postvaricella purpura fulminans or thrombosis. J Pediatr 1996; 128:319-323.
37. Guglielmone H, Vitozzi S, Elbarcha O, et al. Cofactor dependence and isotype distribution of anticardiolipin antibodies in viral infections. Ann Rheum Dis 2001; 60:500-504.
38. Lockwood CJ, Romero R, Feinberg RF, et al. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. Am J Obstet Gynecol 1989; 161:369-373.
39. Harris EN, Spinnato JA. Should anticardiolipin tests be performed in otherwise healthy pregnant women? Am J Obstet Gynecol 1991; 165:1272-1277.
40. Carp HJA, Toder V, Mashiach S, et al. Recurrent miscarriage: a review of current concepts, immune mechanisms and results of treatment. Obstet Gynecol Surv 1990; 45:657-669.
41. Rai RS, Regan L, Clifford K, et al. Antiphospholipid antibodies and beta 2-glycoprotein-1 in 500 women with recurrent miscarriage: results of a comprehensive screening approach. Hum Reprod 1995; 10:2001-2005.
42. Vinatier D, Dufour P, Cosson M, et al. Antiphospholipid syndrome and recurrent miscarriages. Eur J Obst Gynecol Reprod Biol 2001; 96:37-50.
43. Drakeley AJ, Quenby S, Farquharson RG. Mid-trimester loss-appraisal of a screening protocol. Hum Reprod 1998; 13:1975-1980.
44. Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine 2001; 80:1-23.
45. Lyden T, Vogt E, Ng AK, et al. Monoclonal antiphospholipid antibody reactivity against human placental trophoblast. J Reprod Immunol 1992; 22:1-14.
46. Backos M, Rai R, Regan L. Antiphospholipid antibodies and infertility. Hum Fertil 2002; 5:30-34.
47. Rai RS, Clifford K, Cohen H, et al. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod 1995; 10:3301-3304.
48. Carp HJA, Toder V, Mashiach S, et al. Early pregnancy loss: current concepts of research and treatment. Obstet Gynecol Surv 1990; 45:657-669.
49. Carp HJA, Cohen S, Dulitzki M. Antiphospholipid antibody syndrome and pregnancy. In: Dasgupta S, editor. Recent advances in obstetrics and gynaecology. New Delhi: Jaypee Ltd; 1997. Chapter 3, pp 54-73.
50. Oshiro BT, Silver RM, Scott JR, et al. Antiphospholipid antibodies and fetal death. Obstet Gynecol 1996; 87:489-493.
51. Loizou S, Byron MA, Englert HJ, et al. Association of quantitative anticardiolipin antibody levels with fetal loss and time of loss in systemic lupus erythematosus. Q J Med 1988; 255:525-531.
52. Cowchock S, Reece EA. Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Organizing Group of the Antiphospholipid Antibody Treatment Trial . Am J Obstet Gynecol 1997; 176:1099-1100.
53. Pattison NS, Chamley LW, Birdsall M, et al. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. Am J Obstet Gynecol 2000; 183:1008-1012.
54. Tulppala M, Marttunen M, Soderstrom-Anttila V, et al. Low-dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect on prostacyclin and thromboxane A2 production. Hum Reprod 1997; 12:1567-1572.
55. Empson M, Lassere M, Craig JC, et al. Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obstet Gynecol 2002; 99:135-144. A systematic review of therapeutic trials with aspirin for APS. Also appears in Cochrane database, and shows that there is no evidence that aspirin has an effect on the live birth rate.
56. Philipp T, Kalousek DK. Transcervical embryoscopy in missed abortion. J Assist Reprod Genet 2001; 18:285-290.
57. Stern JJ, Dorfman AD, Gutierez-Najar MD. Frequency of abnormal karyotype among abortuses from women with and without a history of recurrent spontaneous abortion. Fertil Steril 1996; 65:250-253.
58. Ogasawara M, Aoki K, Okada S, et al. Embryonic karyotype of abortuses in relation to the number of previous miscarriages. Fertil Steril 2000; 73:300-304.
59. Carp HJA, Toder V, Orgad S, et al. Karyotype of the abortus in recurrent miscarriage. Fertil Steril 2001; 5:678-682.
60. Takakuwa K, Asano K, Arakawa M, et al. Chromosome analysis of aborted conceptuses of recurrent aborters positive for anticardiolipin antibody. Fertil Steril 1997; 68:54-58.
61. Cowchock FS, Reece EA, Balaban D, et al. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomised trial comparing prednisone with low-dose heparin. Am J Obstet Gynecol 1992; 166:1318-1323.
62. Silver RK, MacGregor SN, Sholl JS, et al. Comparative trial of prednisone plus aspirin vs. aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am J Obstet Gynecol 1993; 169:1411-1417.
63. Tincani A, Branch DW, Levy RA, et al. Treatment of pregnant patients with antiphospholipid syndrome. Lupus 2003; 12:524-529. A paper which describes current prescribing practice in APS after questioning 16 leading centres.
64. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174:1584-1589.
65. Rai R, Cohen H, Dave M, et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314:253-257.
66. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Lupus 2002; 100:408-413.
67. Spinnato JA, Clark AL, Pierangeli SS, et al. Intravenous immunoglobulin therapy for the antiphospholipid syndrome in pregnancy. Am J Obstet Gynecol 1995; 172:690-694.
68. Clark AL, Branch DW, Silver RM, et al. Pregnancy complicated by the antiphospholipid syndrome: outcomes with intravenous immunoglobulin therapy. Obstet Gynecol 1999; 93:437-441.
69. Marzusch K, Dietl J, Klein R, et al. Recurrent first trimester spontaneous abortion associated with antiphospholipid antibodies: a pilot study of treatment with intravenous immunoglobulin. Acta Obstet Gynecol Scand 1996; 75:922-926.
70. Vaquero E, Lazzarin N, Valensise H, et al. Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies: a comparative study of intravenous immunoglobulin versus prednisone plus low-dose aspirin. Am J Reprod Immunol 2001; 45:174-179.
71. Branch DW, Peaceman AM, Druzin M, et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol 2000; 182:122-127.
72. Harris EN, Pierangeli SS. Utilization of intravenous immunoglobulin therapy to treat recurrent pregnancy loss in the antiphospholipid syndrome: a review. Scand J Rheumatol Suppl 1998; 107:97-102.
73. Valensie H, Vaquero E, De Carolis C. Normal fetal growth in women with antiphospholipid syndrome treated with high dose intravenous immunoglobulin (IVIG). Prenat Diag 1995; 15:509-517.
74. Kwak JY, Quilty EA, Gilman-Sachs A, et al. Intravenous immunoglobulin infusion therapy in women with recurrent spontaneous abortions of immune etiologies. J Reprod Immunol 1995; 28:175-188.